PMC:7536954 / 157-459 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":66,"end":70},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7163"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":66,"end":70},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000014"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":0,"end":24},"obj":"Disease"},{"id":"T7","span":{"begin":26,"end":28},"obj":"Disease"},{"id":"T8","span":{"begin":53,"end":78},"obj":"Disease"},{"id":"T9","span":{"begin":66,"end":78},"obj":"Disease"},{"id":"T10","span":{"begin":260,"end":265},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0006501"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005093"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":33,"end":34},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/UBERON_0000014"},{"id":"T3","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/UBERON_0001003"},{"id":"T4","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/UBERON_0002097"},{"id":"T5","span":{"begin":66,"end":70},"obj":"http://purl.obolibrary.org/obo/UBERON_0002199"},{"id":"T6","span":{"begin":66,"end":70},"obj":"http://www.ebi.ac.uk/efo/EFO_0000962"},{"id":"T7","span":{"begin":260,"end":287},"obj":"http://purl.obolibrary.org/obo/PR_000000134"},{"id":"T8","span":{"begin":289,"end":292},"obj":"http://purl.obolibrary.org/obo/PR_000000134"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":26,"end":28},"obj":"Chemical"},{"id":"T2","span":{"begin":151,"end":162},"obj":"Chemical"},{"id":"T3","span":{"begin":164,"end":173},"obj":"Chemical"},{"id":"T4","span":{"begin":282,"end":287},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_26537"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_30216"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":260,"end":287},"obj":"Gene"},{"id":"30","span":{"begin":288,"end":295},"obj":"Gene"},{"id":"33","span":{"begin":164,"end":173},"obj":"Chemical"},{"id":"34","span":{"begin":224,"end":234},"obj":"Chemical"},{"id":"38","span":{"begin":0,"end":24},"obj":"Disease"},{"id":"39","span":{"begin":66,"end":78},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:7124"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:7124"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D012176"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D000068879"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D017497"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D012871"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T3","span":{"begin":0,"end":24},"obj":"Phenotype"},{"id":"T4","span":{"begin":26,"end":28},"obj":"Phenotype"},{"id":"T5","span":{"begin":53,"end":78},"obj":"Phenotype"},{"id":"T6","span":{"begin":260,"end":265},"obj":"Phenotype"}],"attributes":[{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0040154"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0040154"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0011123"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":266,"end":274},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T2","span":{"begin":266,"end":274},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T3","span":{"begin":266,"end":274},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T4","span":{"begin":266,"end":274},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":302},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Hidradenitis suppurativa (HS) is a chronic disabling inflammatory skin disease that, in moderate to severe cases, usually requires the use of systemic antibiotics, retinoids, and immunosuppressants/immunomodulants including adalimumab, the first‐approved anti‐tumor necrosis factor‐alpha (TNF)‐α agent."}